## Parkinson Disease and Basal Ganglia Circuit Dysfunction ### Normal vs. Parkinsonian Basal Ganglia Physiology **Key Point:** Parkinson disease results from selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), disrupting the balance between direct and indirect pathways. ### Cascade of Changes in Parkinson Disease ```mermaid flowchart TD A[Loss of SNpc dopaminergic neurons]:::urgent --> B[↓ Dopamine in striatum]:::outcome B --> C[↓ D1 activation<br/>Direct pathway suppressed]:::action B --> D[↑ D2 activation<br/>Indirect pathway enhanced]:::action C --> E[↑ SNr/GPi inhibition<br/>of thalamus]:::outcome D --> F[↓ GPe inhibition<br/>of STN]:::outcome F --> G[↑ STN excitation<br/>of SNr/GPi]:::outcome E --> H[Excessive thalamic inhibition]:::urgent G --> H H --> I[Bradykinesia, Rigidity, Tremor]:::outcome ``` ### Step-by-Step Pathophysiology 1. **Dopamine loss** → Direct pathway hypoactivity (D1 neurons less excited) 2. **Dopamine loss** → Indirect pathway hyperactivity (D2 neurons less inhibited) 3. **Indirect pathway hyperactivity** → GPe becomes less inhibited by striatum → GPe less able to inhibit STN 4. **STN hyperactivity** → Increased glutamatergic drive to SNr/GPi 5. **Net result:** Excessive GABAergic inhibition of thalamus → movement suppression **High-Yield:** The **external globus pallidus (GPe) becomes HYPOACTIVE** (not hyperactive) in Parkinson disease because it receives less inhibitory input from the striatum due to indirect pathway hyperactivity. The GPe does NOT directly inhibit the thalamus; it modulates the STN. The statement claiming GPe directly inhibits thalamus and causes symptoms independent of STN changes is **anatomically incorrect** and is the wrong answer. ### Levodopa Mechanism **Mnemonic:** **L-DOPA = Restore D1 > D2 balance** - Levodopa is converted to dopamine in the striatum - Dopamine preferentially activates **D1 receptors** (direct pathway) at therapeutic doses - This **enhances direct pathway** (movement facilitation) and **suppresses indirect pathway** (movement inhibition) - Result: Reduced bradykinesia and rigidity **Clinical Pearl:** Early Parkinson disease responds well to levodopa because the remaining dopaminergic neurons can still synthesize and release dopamine. As disease progresses and more neurons are lost, levodopa efficacy wanes and motor fluctuations emerge. ### Role of Subthalamic Nucleus **Key Point:** The STN is **hyperactive** in Parkinson disease and is a critical therapeutic target. Deep brain stimulation of the STN is highly effective because it disrupts the excessive glutamatergic drive to SNr/GPi. **Warning:** Do NOT confuse GPe (external globus pallidus) with GPi (internal globus pallidus). The GPe modulates the STN; the GPi is the output nucleus that inhibits the thalamus. In Parkinson disease, GPe hypoactivity leads to STN hyperactivity, which then increases GPi output. [cite:Kandel Principles of Neural Science 6e Ch 42; Harrison 21e Ch 428]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.